Search Result
Results for "
PEG-1000
" in MedChemExpress (MCE) Product Catalog:
109
Biochemical Assay Reagents
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-Y0873G
-
|
Polyethylene glycol 1000
|
Biochemical Assay Reagents
|
Others
|
|
PEG1000 can be used as an excipient, such as Ointment base, lubricant, etc. Pharmaceutical excipients, or pharmaceutical auxiliaries, refer to other chemical substances used in the pharmaceutical process other than pharmaceutical ingredients. Pharmaceutical excipients generally refer to inactive ingredients in pharmaceutical preparations, which can improve the stability, solubility and processability of pharmaceutical preparations. Pharmaceutical excipients also affect the absorption, distribution, metabolism, and elimination (ADME) processes of co-administered drugs .
|
-
-
- HY-155927
-
|
14:0 PEG1000 PE ammonium; 1,2-Dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-1000] ammonium
|
Liposome
|
Others
|
|
DMPE-PEG1000 ammonium (14:0 PEG1000 PE ammonium) is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.
|
-
-
- HY-155932
-
|
DOPE-PEG1000 ammonium; 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-1000] ammonium
|
Liposome
|
Others
|
|
18:1 PEG1000 PE ammonium (DOPE-PEG1000 ammonium) is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.
|
-
-
- HY-167056
-
|
PLLA4000-PEG1000-Vinylsulfone
|
Biochemical Assay Reagents
|
Others
|
|
PLLA4000-PEG1000-VS (PLLA4000-PEG1000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
-
- HY-167020
-
|
PLGA3000-PEG1000-Vinylsulfone
|
Biochemical Assay Reagents
|
Others
|
|
PLGA3000-PEG1000-VS (PLGA3000-PEG1000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
-
- HY-167034
-
|
PLGA5000-PEG1000-Vinylsulfone
|
Biochemical Assay Reagents
|
Others
|
|
PLGA5000-PEG1000-VS (PLGA5000-PEG1000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
-
- HY-167060
-
|
PLLA3000-PEG1000-Vinylsulfone
|
Biochemical Assay Reagents
|
Others
|
|
PLLA3000-PEG1000-VS (PLLA3000-PEG1000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
-
- HY-167052
-
|
PLLA2000-PEG1000-Vinylsulfone
|
Biochemical Assay Reagents
|
Others
|
|
PLLA2000-PEG1000-VS (PLLA2000-PEG1000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
-
- HY-167040
-
|
PLLA10000-PEG1000-Vinylsulfone
|
Biochemical Assay Reagents
|
Others
|
|
PLLA10000-PEG1000-VS (PLLA10000-PEG1000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
-
- HY-167008
-
|
PLGA1000-PEG1000-Vinylsulfone
|
Biochemical Assay Reagents
|
Others
|
|
PLGA1000-PEG1000-VS (PLGA1000-PEG1000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
-
- HY-167046
-
|
PLLA1000-PEG1000-Vinylsulfone
|
Biochemical Assay Reagents
|
Others
|
|
PLLA1000-PEG1000-VS (PLLA1000-PEG1000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
-
- HY-167047
-
|
PLLA5000-PEG1000-Vinylsulfone
|
Biochemical Assay Reagents
|
Others
|
|
PLLA5000-PEG1000-VS (PLLA5000-PEG1000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
-
- HY-167029
-
|
PLGA4000-PEG1000-Vinylsulfone
|
Biochemical Assay Reagents
|
Others
|
|
PLGA4000-PEG1000-VS (PLGA4000-PEG1000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
-
- HY-167014
-
|
PLGA2000-PEG1000-Vinylsulfone
|
Biochemical Assay Reagents
|
Others
|
|
PLGA2000-PEG1000-VS (PLGA2000-PEG1000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
-
- HY-167372
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA5000-PEG1000-BIO is a polylactic acid derivative that can form micelles in water. In addition, PLLA5000-PEG1000-BIO can bind tightly to avidin or streptavidin for protein labeling. PLLA5000-PEG1000-BIO can be used in drug delivery research .
|
-
-
- HY-167384
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA1000-PEG1000-BIO is a polylactic acid derivative that can form micelles in water. In addition, PLLA1000-PEG1000-BIO can bind tightly to avidin or streptavidin for protein labeling. PLLA1000-PEG1000-BIO can be used in drug delivery research .
|
-
-
- HY-167381
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA2000-PEG1000-BIO is a polylactic acid derivative that can form micelles in water. In addition, PLLA2000-PEG1000-BIO can bind tightly to avidin or streptavidin for protein labeling. PLLA2000-PEG1000-BIO can be used in drug delivery research .
|
-
-
- HY-167378
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA3000-PEG1000-BIO is a polylactic acid derivative that can form micelles in water. In addition, PLLA3000-PEG1000-BIO can bind tightly to avidin or streptavidin for protein labeling. PLLA3000-PEG1000-BIO can be used in drug delivery research .
|
-
-
- HY-167387
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA10000-PEG1000-BIO is a polylactic acid derivative that can form micelles in water. In addition, PLLA10000-PEG1000-BIO can bind tightly to avidin or streptavidin for protein labeling. PLLA10000-PEG1000-BIO can be used in drug delivery research .
|
-
-
- HY-167375
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA4000-PEG1000-BIO is a polylactic acid derivative that can form micelles in water. In addition, PLLA4000-PEG1000-BIO can bind tightly to avidin or streptavidin for protein labeling. PLLA4000-PEG1000-BIO can be used in drug delivery research .
|
-
-
- HY-167395
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA4000-PEG1000-ALK is a polylactic acid derivative that can form micelles in water. PLLA4000-PEG1000-ALK can be used in drug delivery research .
|
-
-
- HY-167391
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA5000-PEG1000-ALK is a polylactic acid derivative that can form micelles in water. PLLA5000-PEG1000-ALK can be used in drug delivery research .
|
-
-
- HY-167403
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA2000-PEG1000-ALK is a polylactic acid derivative that can form micelles in water. PLLA2000-PEG1000-ALK can be used in drug delivery research .
|
-
-
- HY-167407
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA1000-PEG1000-ALK is a polylactic acid derivative that can form micelles in water. PLLA1000-PEG1000-ALK can be used in drug delivery research .
|
-
-
- HY-167399
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA3000-PEG1000-ALK is a polylactic acid derivative that can form micelles in water. PLLA3000-PEG1000-ALK can be used in drug delivery research .
|
-
-
- HY-167488
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA1000-PEG1000-RhB is a terminal rhodamine-labeled polylactic acid derivative. PLLA1000-PEG1000-RhB can be used to label nanomicelles for real-time monitoring of drug release in vivo .
|
-
-
- HY-167492
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA10000-PEG1000-RhB is a terminal rhodamine-labeled polylactic acid derivative. PLLA10000-PEG1000-RhB can be used to label nanomicelles for real-time monitoring of drug release in vivo .
|
-
-
- HY-167480
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA3000-PEG1000-RhB is a terminal rhodamine-labeled polylactic acid derivative. PLLA3000-PEG1000-RhB can be used to label nanomicelles for real-time monitoring of drug release in vivo .
|
-
-
- HY-167472
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA5000-PEG1000-RhB is a terminal rhodamine-labeled polylactic acid derivative. PLLA5000-PEG1000-RhB can be used to label nanomicelles for real-time monitoring of drug release in vivo .
|
-
-
- HY-167484
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA2000-PEG1000-RhB is a terminal rhodamine-labeled polylactic acid derivative. PLLA2000-PEG1000-RhB can be used to label nanomicelles for real-time monitoring of drug release in vivo .
|
-
-
- HY-167476
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA4000-PEG1000-RhB is a terminal rhodamine-labeled polylactic acid derivative. PLLA4000-PEG1000-RhB can be used to label nanomicelles for real-time monitoring of drug release in vivo .
|
-
-
- HY-167321
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA5000-PEG1000-SPDP is a polylactic acid derivative that can form micelles in water and the SPDP moiety can react with thiols. PLLA5000-PEG1000-SPDP can be used in drug delivery research .
|
-
-
- HY-167325
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA4000-PEG1000-SPDP is a polylactic acid derivative that can form micelles in water and the SPDP moiety can react with thiols. PLLA4000-PEG1000-SPDP can be used in drug delivery research .
|
-
-
- HY-167305
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA3000-PEG1000-Thiol is a polylactic acid derivative that forms micelles in water and initiates biodegradation by attacking ester bonds through hydrolysis. PLLA3000-PEG1000-Thiol can be used in drug delivery research .
|
-
-
- HY-167333
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA2000-PEG1000-SPDP is a polylactic acid derivative that can form micelles in water and the SPDP moiety can react with thiols. PLLA2000-PEG1000-SPDP can be used in drug delivery research .
|
-
-
- HY-167341
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA10000-PEG1000-SPDP is a polylactic acid derivative that can form micelles in water and the SPDP moiety can react with thiols. PLLA10000-PEG1000-SPDP can be used in drug delivery research .
|
-
-
- HY-167301
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA4000-PEG1000-Thiol is a polylactic acid derivative that forms micelles in water and initiates biodegradation by attacking ester bonds through hydrolysis. PLLA4000-PEG1000-Thiol can be used in drug delivery research .
|
-
-
- HY-167309
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA2000-PEG1000-Thiol is a polylactic acid derivative that forms micelles in water and initiates biodegradation by attacking ester bonds through hydrolysis. PLLA2000-PEG1000-Thiol can be used in drug delivery research .
|
-
-
- HY-167297
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA5000-PEG1000-Thiol is a polylactic acid derivative that forms micelles in water and initiates biodegradation by attacking ester bonds through hydrolysis. PLLA5000-PEG1000-Thiol can be used in drug delivery research .
|
-
-
- HY-167317
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA10000-PEG1000-Thiol is a polylactic acid derivative that forms micelles in water and initiates biodegradation by attacking ester bonds through hydrolysis. PLLA10000-PEG1000-Thiol can be used in drug delivery research .
|
-
-
- HY-167313
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA1000-PEG1000-Thiol is a polylactic acid derivative that forms micelles in water and initiates biodegradation by attacking ester bonds through hydrolysis. PLLA1000-PEG1000-Thiol can be used in drug delivery research .
|
-
-
- HY-167337
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA1000-PEG1000-SPDP is a polylactic acid derivative that can form micelles in water and the SPDP moiety can react with thiols. PLLA1000-PEG1000-SPDP can be used in drug delivery research .
|
-
-
- HY-167329
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA3000-PEG1000-SPDP is a polylactic acid derivative that can form micelles in water and the SPDP moiety can react with thiols. PLLA3000-PEG1000-SPDP can be used in drug delivery research .
|
-
-
- HY-167462
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA1000-PEG1000-N3 is a polylactic acid derivative used for encapsulating hydrophobic drugs. PLLA1000-PEG1000-N3 can be used in drug delivery research .
|
-
-
- HY-167450
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA4000-PEG1000-N3 is a polylactic acid derivative used for encapsulating hydrophobic drugs. PLLA4000-PEG1000-N3 can be used in drug delivery research .
|
-
-
- HY-167458
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA2000-PEG1000-N3 is a polylactic acid derivative used for encapsulating hydrophobic drugs. PLLA2000-PEG1000-N3 can be used in drug delivery research .
|
-
-
- HY-167454
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA3000-PEG1000-N3 is a polylactic acid derivative used for encapsulating hydrophobic drugs. PLLA3000-PEG1000-N3 can be used in drug delivery research .
|
-
-
- HY-167466
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA10000-PEG1000-N3 is a polylactic acid derivative used for encapsulating hydrophobic drugs. PLLA10000-PEG1000-N3 can be used in drug delivery research .
|
-
-
- HY-167446
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA5000-PEG1000-N3 is a polylactic acid derivative used for encapsulating hydrophobic drugs. PLLA5000-PEG1000-N3 can be used in drug delivery research .
|
-
-
- HY-172680
-
|
|
Liposome
|
Inflammation/Immunology
|
|
DSPE-PEG1000-VIP is a PEG compound which composed of DSPE and a vasoactive intestinal peptide (VIP). DSPE-PEG1000-VIP can be used for drug delivery .
|
-
- HY-172278
-
|
|
Liposome
|
Cancer
|
|
DSPE-PEG1000-CGKRK is a PEG compound which composed of DSPE and a cell-penetrating peptide (CGKRK). DSPE-PEG1000-CGKRK can be used for drug delivery .
|
-
- HY-167428
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA3000-PEG1000-NH2 is a block copolymer based on polylactic acid derivatives that can self-assemble in water. PLLA3000-PEG1000-NH2 can be used in drug delivery research .
|
-
- HY-167424
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA4000-PEG1000-NH2 is a block copolymer based on polylactic acid derivatives that can self-assemble in water. PLLA4000-PEG1000-NH2 can be used in drug delivery research .
|
-
- HY-167433
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA2000-PEG1000-NH2 is a block copolymer based on polylactic acid derivatives that can self-assemble in water. PLLA2000-PEG1000-NH2 can be used in drug delivery research .
|
-
- HY-167420
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA5000-PEG1000-NH2 is a block copolymer based on polylactic acid derivatives that can self-assemble in water. PLLA5000-PEG1000-NH2 can be used in drug delivery research .
|
-
- HY-167438
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA1000-PEG1000-NH2 is a block copolymer based on polylactic acid derivatives that can self-assemble in water. PLLA1000-PEG1000-NH2 can be used in drug delivery research .
|
-
- HY-167442
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA10000-PEG1000-NH2 is a block copolymer based on polylactic acid derivatives that can self-assemble in water. PLLA10000-PEG1000-NH2 can be used in drug delivery research .
|
-
- HY-143209A
-
-
- HY-145396A
-
-
- HY-167357
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA3000-PEG1000-PLLA3000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA3000-PEG1000-PLLA3000 can be used in drug delivery research .
|
-
- HY-167363
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA2000-PEG1000-PLLA2000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA2000-PEG1000-PLLA2000 can be used in drug delivery research .
|
-
- HY-167139
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA8000-PEG1000-PLLA8000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA8000-PEG1000-PLLA8000 can be used in drug delivery research .
|
-
- HY-167345
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA5000-PEG1000-PLLA5000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA5000-PEG1000-PLLA5000 can be used in drug delivery research .
|
-
- HY-167120
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA6000-PEG1000-PLLA6000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA6000-PEG1000-PLLA6000 can be used in drug delivery research .
|
-
- HY-167369
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA1000-PEG1000-PLLA1000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA1000-PEG1000-PLLA1000 can be used in drug delivery research .
|
-
- HY-167351
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA4000-PEG1000-PLLA4000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA4000-PEG1000-PLLA4000 can be used in drug delivery research .
|
-
- HY-172279
-
|
|
Liposome
|
Infection
|
|
DSPE-PEG1000-TAT is a PEG compound which composed of DSPE and a cell-penetrating peptide (TAT) (HY-P0281). DSPE-PEG1000-TAT can be used for drug delivery .
|
-
- HY-173385
-
|
|
Biochemical Assay Reagents
|
Metabolic Disease
|
|
Cholesteryl-PEG1000-Azide is a lipid that can be used for drug delivery. Cholesteryl-PEG1000-Azide is attached to the cholesterol backbone with a PEG unit on one side and an azide unit on the other side of the PEG. Cholesteryl-PEG1000-Azide contains an azide group that can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing an alkyne group .
|
-
- HY-144012D
-
|
16:0 PEG1000 PE; 1,2-Dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-1000] ammonium
|
Liposome
|
Others
|
|
DPPE-PEG1000 is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.
|
-
- HY-172274
-
|
|
Liposome
|
Cancer
|
|
DSPE-PEG1000-APRPG is a PEG compound which composed of DSPE and a APRPG peptide. DSPE-PEG1000-APRPG can be used for drug delivery .
|
-
- HY-172481
-
|
|
Liposome
|
Cancer
|
|
DSPE-PEG1000-TAASGVRSMH is a PEG compound which composed of DSPE and TAASGVRSMH. TAASGVRSMH has a strong affinity for the NG2 proteoglycan on the PC membrane. DSPE-PEG1000-TAASGVRSMH can be used for drug delivery .
|
-
- HY-172686
-
|
|
Liposome
|
Cardiovascular Disease
|
|
DSPE-PEG1000-CSTSMLKAC is a PEG compound which composed of DSPE and a peptide (CSTSMLKAC). CSTSMLKAC is capable of mediating selective homing of phage to ischemic heart tissue. DSPE-PEG1000-CSTSMLKAC can be used for drug delivery .
|
-
- HY-172472
-
|
|
Liposome
|
Cancer
|
|
DSPE-PEG1000-NGR is a PEG compound which composed of DSPE and an Asn-Gly-Arg (NGR) peptide. NGR peptide can target tumor vascular antigen CD13. DSPE-PEG1000-NGR can be used for drug delivery .
|
-
- HY-172683
-
|
|
Liposome
|
Others
|
|
DSPE-PEG1000-GRGDS is a PEG compound which composed of DSPE and an anti-adhesion peptide (GRGDS). GRGDS can block the binding and adhesion of extracellular matrix to cell surface integrins. DSPE-PEG1000-GRGDS can be used for drug delivery .
|
-
- HY-172725
-
|
|
Liposome
|
Cancer
|
|
DSPE-PEG1000-EB1 is a PEG compound which composed of DSPE and pH responsive membrane-penetrating peptide (EB1). DSPE-PEG1000-EB1 can be used for drug delivery .
|
-
- HY-172277
-
|
|
Liposome
|
Neurological Disease
|
|
DSPE-PEG1000-R9 is a PEG compound which composed of DSPE and a poly-arginine-9 peptide (R9). DSPE-PEG1000-R9 can be used for drug delivery .
|
-
- HY-172695
-
|
|
Liposome
|
Inflammation/Immunology
|
|
DSPE-PEG1000-WYRGRL is a PEG compound which composed of DSPE and a cartilage-targeting peptide (WYRGRL). WYRGRL is a collagen II-targeting peptide that can bind to collagen II α1. DSPE-PEG1000-WYRGRL can be used for drug delivery .
|
-
- HY-172276
-
|
|
Liposome
|
Cancer
|
|
DSPE-PEG1000-R8 is a PEG compound which composed of DSPE and a cell-penetrating peptide (R8). pDSPE-PEG1000-R8 can be used for drug delivery .
|
-
- HY-172484
-
|
|
Liposome
|
Cancer
|
|
DSPE-PEG1000-LTLRWVGLMS is a PEG compound which composed of DSPE and a decapeptide (LTLRWVGLMS). The chondroitin sulfate proteoglygan NG2 is a receptor for LTLRWVGLMS. LLRWVGLMS shows the homing of pericytes associated with tumor blood vessels. DSPE-PEG1000-LTLRWVGLMS can be used for drug delivery .
|
-
- HY-172707
-
|
|
Liposome
|
Neurological Disease
|
|
DSPE-PEG1000-PP1 is a PEG compound which composed of DSPE and a PP1 peptide. PP1 peptide targets the inflammatory atherosclerotic plaque. DSPE-PEG1000-PP1 can be used for drug delivery .
|
-
- HY-168374A
-
-
- HY-172270
-
|
|
Liposome
|
Cancer
|
|
DSPE-PEG1000-PTP is synthesised by conjugating the amino group of plectin-1 peptide (PTP) with DSPE-PEG-NHS ester via amide bonds. DSPE-PEG1000-PTP can be used to construct drug delivery vectors .
|
-
- HY-172280
-
|
|
Liposome
|
Cancer
|
|
DSPE-PEG1000-Octreotide is a PEG compound which composed of DSPE and a Octreotide (HY-P0036). Octreotide is a somatostatin receptor agonist. Octreotide has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly. DSPE-PEG1000-Octreotide can be used for drug delivery .
|
-
- HY-172698
-
|
|
Liposome
|
Cancer
|
|
DSPE-PEG1000-ANG is a PEG compound which composed of DSPE and a dual-targeting ligand (Angiopep-2, ANG). ANG exhibits high LRP1 binding efficiency and has been used for glioma-targeting delivery. DSPE-PEG1000-ANG can be used for drug delivery .
|
-
- HY-172701
-
|
|
Liposome
|
Cancer
|
|
DSPE-PEG1000-NYZL1 is a PEG compound which composed of DSPE and a NYZL1 peptide. NYZL1 can specifically bind to bladder cancer tissues and cells. DSPE-PEG1000-NYZL1 can be used for drug delivery .
|
-
- HY-172466
-
|
|
Liposome
|
Cancer
|
|
DSPE-PEG1000-CTT2 is a PEG compound which composed of DSPE and a gelatinase inhibitor (CTT2 (CTTHWGFTLC)). CTT2 (CTTHWGFTLC) has the ability to specifically target tumors. DSPE-PEG1000-CTT2 can be used for drug delivery .
|
-
- HY-172469
-
|
|
Liposome
EGFR
|
Cancer
|
|
DSPE-PEG1000-GE11 is a PEG compound which composed of DSPE and an EGFR targeting peptide (GE11). GE11 can be used for EGFR overexpressed cancer cells. DSPE-PEG1000-GE11 can be used for drug delivery .
|
-
- HY-172463
-
|
|
Liposome
Integrin
|
Cancer
|
|
DSPE-PEG1000-cRGD is a PEG compound which composed of DSPE and an αvβ3 targeting peptide (cRGD). cRGD peptide can specifically bind to αvβ3 on the surface of many cancer cells and neovascular cells. DSPE-PEG1000-cRGD can be used for drug delivery .
|
-
- HY-172502
-
|
|
Liposome
|
Cancer
|
|
DSPE-PEG1000-KAA is a PEG compound which composed of DSPE and a CKAAKNK peptide (KAA). KAA specifically binds to tumor vessels in RIP-Tag2 transgenic mice. DSPE-PEG1000-KAA can be used for drug delivery .
|
-
- HY-172722
-
|
|
Liposome
|
Cancer
|
|
DSPE-PEG1000-T7 is a PEG compound which composed of DSPE and a transferrin receptor (TfR) peptide (T7). T7 (HAIYPRH) specifically binds to TfR (transferrin receptor). DSPE-PEG1000-T7 can be used for drug delivery .
|
-
- HY-172475
-
|
|
Liposome
|
Cancer
|
|
DSPE-PEG1000-YIGSR is a PEG compound which composed of DSPE and a biomimetic peptide YIGSR. YIGSR interacts with the 67 kDa laminin binding protein (LBP) and promotes adhesion and spreading of a large number of cell types including endothelial cells, fibroblasts and smooth muscle cells. DSPE-PEG1000-YIGSR can be used for drug delivery .
|
-
- HY-172496
-
|
|
Liposome
|
Cancer
|
|
DSPE-PEG1000-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG1000-CREKA can be used for drug delivery .
|
-
- HY-172281
-
|
|
Liposome
|
Cardiovascular Disease
|
|
DSPE-PEG1000-CCK8 is a PEG compound which composed of DSPE and a Cholecystokinin-8 (CCK8). Cholecystokinin-8 has the activity of peptide regulating gallbladder contraction and digestive system function. DSPE-PEG1000-CCK8 can be used for drug delivery .
|
-
- HY-173381A
-
|
Cholesteryl biotinyl(polyethyleneglycol)-1000 carbamate
|
Biochemical Assay Reagents
|
Others
|
|
Cholesteryl-PEG1000-Biotin is a lipid product. Cholesteryl-PEG1000-Biotin is a cholesterol backbone attached to one side of a PEG unit and a Biotin unit on the other side. Biotin is an enzyme cofactor that can be used to label proteins, and PEG is a low-toxic, hydrophilic, water-soluble polymer. Cholesteryl-PEG1000-Biotin can be used for drug circulation time studies .
|
-
- HY-172493
-
|
|
Liposome
Integrin
|
Cancer
|
|
DSPE-PEG1000-iRGD is a PEG compound which composed of DSPE and an αv-integrins targeting peptide (iRGD). iRGD peptide binds to αv-integrins, and then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties. DSPE-PEG1000-iRGD can be used for drug delivery .
|
-
- HY-172478
-
|
|
Liposome
|
Cancer
|
|
DSPE-PEG1000-F3 is a PEG compound which composed of DSPE and a nucleolin targeting peptide (F3). F3 peptide can specifically bind to cell surface nucleolin and undergo an effective cell surface to nucleus transport. DSPE-PEG1000-F3 can be used for drug delivery .
|
-
- HY-172487
-
|
|
Liposome
|
Cancer
|
|
DSPE-PEG1000-K237 is a PEG compound which composed of DSPE and a KDR targeting peptide (K237). K237 can functionally disrupt the interaction between VEGF and the KDR receptor and cause potent biological effects that include the inhibition of angiogenesis and tumor growth. DSPE-PEG1000-K237 can be used for drug delivery .
|
-
- HY-138312
-
|
|
PROTAC Linkers
|
Cancer
|
|
m-PEG1000-CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs .
|
-
- HY-172689
-
|
|
Liposome
|
Cancer
|
|
DSPE-PEG1000-THRPPMWSPVWP is a PEG compound which composed of DSPE and a transferrin receptor (TfR) peptide (THRPPMWSPVWP). THRPPMWSPVWP binds to the TfR and is subsequently internalized into TfR-expressing cells .
|
-
- HY-172275
-
|
|
Liposome
|
Inflammation/Immunology
|
|
DSPE-PEG1000-pPB is a PEG compound which composed of DSPE and a cyclic oligopeptide (pPB). pPB has a strong binding affinity with PDGFRβ, which is overexpressed on activated hepatic stellate cells (HSC). DSPE-PEG1000-pPB can be used for drug delivery .
|
-
- HY-172273
-
|
|
Liposome
|
Cancer
|
|
DSPE-PEG1000-M2pep is a PEG compound which composed of DSPE and a M2-polarized macrophages targeting peptide (M2pep). M2pep is conjugated to a proapoptotic peptide as monovalent or multivalent ligands to concentrate the toxic effect of the peptide to M2 macrophages. DSPE-PEG1000-M2pep can be used for drug delivery .
|
-
- HY-172710
-
|
|
Liposome
|
Cancer
|
|
DSPE-PEG1000-R6H4 is a PEG compound which composed of DSPE and pH responsive membrane-penetrating peptide (R6H4). R6H4 can be used for pH responsive anticancer drug delivery purposes. DSPE-PEG1000-R6H4 can be used for drug delivery .
|
-
- HY-172490
-
|
|
Liposome
|
Cancer
|
|
DSPE-PEG1000-ESBP is a PEG compound which composed of DSPE and a E-selectin-binding peptide (ESBP). As a tumor-targeting peptide, ESBP can specifically recognize and bind to receptors or markers on the surface of tumor cells .
|
-
- HY-172499
-
|
|
Liposome
|
Cancer
|
|
DSPE-PEG1000-SP94 is a PEG compound which composed of DSPE and a cell-penetrating peptide (SP94). SP94 shows specific binding to hepatocellular carcinoma (HCC) cells .
|
-
- HY-172692
-
|
|
Liposome
|
Cancer
|
|
DSPE-PEG1000-TH is a PEG compound which composed of DSPE and a pH-responsive cell penetrating peptide (TH). TH is activated in an acidic environment (such as the tumor microenvironment) and can selectively carry small molecules, oligonucleotides, proteins, etc. into tumor cells .
|
-
- HY-172704
-
|
|
Liposome
nAChR
|
Cancer
|
|
DSPE-PEG1000-RVG29 is a PEG compound which composed of DSPE and a Rabies virus glycoprotein 29 (RVG29). RVG29 can bind specifically to the nicotinic acetylcholine receptor (nAChR) at the blood-brain barrier (BBB) and cross over the BBB .
|
-
- HY-172283
-
|
|
Liposome
|
Cancer
|
|
DSPE-PEG1000-BR2 is a PEG compound which composed of DSPE and a BR2. BR2 is a targeting peptide composed of 17 amino acids with the sequence RAGLQFPVGRLLRRLLR. It has the ability to assist cells to penetrate the membrane and can specifically target certain cells or tissues .
|
-
- HY-172272
-
|
|
Liposome
VEGFR
|
Cancer
|
|
DSPE-PEG1000-A7R is a PEG compound which composed of DSPE and a tumor vascular targeting peptide (A7R). A7R exhibits high affinity and specificity for VEGFR-2, which is overexpressed in various tumors .
|
-
- HY-172713
-
|
|
Liposome
|
Infection
|
|
DSPE-PEG1000-MPG is a PEG compound which composed of DSPE and a peptide vector (MPG). MPG is derived from both the nuclear localisation sequence (NLS) of SV40 large T antigen and the fusion peptide domain of HIV-1 gp41. MPG could deliver short oligonucleotides into cells efficiently and independently of the endosomal pathway .
|
-
- HY-172271
-
|
|
Liposome
|
Cancer
|
|
DSPE-PEG1000-LyP-1 is a PEG compound which composed of DSPE and a nine residue peptide (LyP-1) (HY-P2526). LyP-1 targets tumor-associated lymphatic vessels and macrophages .
|
-
- HY-172270D
-
|
|
Liposome
|
Cancer
|
|
DSPE-PEG1000-PTP is synthesised by conjugating the amino group of plectin-1 peptide (PTP) with DSPE-PEG-NHS ester via amide bonds. DSPE-PEG1000-PTP can be used to construct drug delivery vectors .
|
-
- HY-172270C
-
|
|
Liposome
|
Cancer
|
|
DSPE-PEG1000-PTP is synthesised by conjugating the amino group of plectin-1 peptide (PTP) with DSPE-PEG-NHS ester via amide bonds. DSPE-PEG1000-PTP can be used to construct drug delivery vectors .
|
-
- HY-172270A
-
|
|
Liposome
|
Cancer
|
|
DSPE-PEG1000-PTP is synthesised by conjugating the amino group of plectin-1 peptide (PTP) with DSPE-PEG-NHS ester via amide bonds. DSPE-PEG1000-PTP can be used to construct drug delivery vectors .
|
-
- HY-D2835
-
|
|
Fluorescent Dye
|
Others
|
|
mPEG-PEI-Cy5 (MW 1000) is a fluorescent dye composed of polyethylene glycol (PEG), FITC (HY-66019) and a Biotin (HY-B0511). mPEG-PEI-Cy5 (MW 1000) can be used for fluorescent labeling and imaging .
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-D2835
-
|
|
Fluorescent Dyes/Probes
|
|
mPEG-PEI-Cy5 (MW 1000) is a fluorescent dye composed of polyethylene glycol (PEG), FITC (HY-66019) and a Biotin (HY-B0511). mPEG-PEI-Cy5 (MW 1000) can be used for fluorescent labeling and imaging .
|
| Cat. No. |
Product Name |
Type |
-
- HY-155927
-
|
14:0 PEG1000 PE ammonium; 1,2-Dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-1000] ammonium
|
Drug Delivery
|
|
DMPE-PEG1000 ammonium (14:0 PEG1000 PE ammonium) is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.
|
-
- HY-155932
-
|
DOPE-PEG1000 ammonium; 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-1000] ammonium
|
Drug Delivery
|
|
18:1 PEG1000 PE ammonium (DOPE-PEG1000 ammonium) is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.
|
-
- HY-167056
-
|
PLLA4000-PEG1000-Vinylsulfone
|
Drug Delivery
|
|
PLLA4000-PEG1000-VS (PLLA4000-PEG1000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
- HY-167020
-
|
PLGA3000-PEG1000-Vinylsulfone
|
Drug Delivery
|
|
PLGA3000-PEG1000-VS (PLGA3000-PEG1000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
- HY-167034
-
|
PLGA5000-PEG1000-Vinylsulfone
|
Drug Delivery
|
|
PLGA5000-PEG1000-VS (PLGA5000-PEG1000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
- HY-167060
-
|
PLLA3000-PEG1000-Vinylsulfone
|
Drug Delivery
|
|
PLLA3000-PEG1000-VS (PLLA3000-PEG1000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
- HY-167052
-
|
PLLA2000-PEG1000-Vinylsulfone
|
Drug Delivery
|
|
PLLA2000-PEG1000-VS (PLLA2000-PEG1000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
- HY-167040
-
|
PLLA10000-PEG1000-Vinylsulfone
|
Drug Delivery
|
|
PLLA10000-PEG1000-VS (PLLA10000-PEG1000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
- HY-167008
-
|
PLGA1000-PEG1000-Vinylsulfone
|
Drug Delivery
|
|
PLGA1000-PEG1000-VS (PLGA1000-PEG1000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
- HY-167046
-
|
PLLA1000-PEG1000-Vinylsulfone
|
Drug Delivery
|
|
PLLA1000-PEG1000-VS (PLLA1000-PEG1000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
- HY-167047
-
|
PLLA5000-PEG1000-Vinylsulfone
|
Drug Delivery
|
|
PLLA5000-PEG1000-VS (PLLA5000-PEG1000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
- HY-167029
-
|
PLGA4000-PEG1000-Vinylsulfone
|
Drug Delivery
|
|
PLGA4000-PEG1000-VS (PLGA4000-PEG1000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
- HY-167014
-
|
PLGA2000-PEG1000-Vinylsulfone
|
Drug Delivery
|
|
PLGA2000-PEG1000-VS (PLGA2000-PEG1000-Vinylsulfone) is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
|
-
- HY-167372
-
|
|
Drug Delivery
|
|
PLLA5000-PEG1000-BIO is a polylactic acid derivative that can form micelles in water. In addition, PLLA5000-PEG1000-BIO can bind tightly to avidin or streptavidin for protein labeling. PLLA5000-PEG1000-BIO can be used in drug delivery research .
|
-
- HY-167384
-
|
|
Drug Delivery
|
|
PLLA1000-PEG1000-BIO is a polylactic acid derivative that can form micelles in water. In addition, PLLA1000-PEG1000-BIO can bind tightly to avidin or streptavidin for protein labeling. PLLA1000-PEG1000-BIO can be used in drug delivery research .
|
-
- HY-167381
-
|
|
Drug Delivery
|
|
PLLA2000-PEG1000-BIO is a polylactic acid derivative that can form micelles in water. In addition, PLLA2000-PEG1000-BIO can bind tightly to avidin or streptavidin for protein labeling. PLLA2000-PEG1000-BIO can be used in drug delivery research .
|
-
- HY-167378
-
|
|
Drug Delivery
|
|
PLLA3000-PEG1000-BIO is a polylactic acid derivative that can form micelles in water. In addition, PLLA3000-PEG1000-BIO can bind tightly to avidin or streptavidin for protein labeling. PLLA3000-PEG1000-BIO can be used in drug delivery research .
|
-
- HY-167387
-
|
|
Drug Delivery
|
|
PLLA10000-PEG1000-BIO is a polylactic acid derivative that can form micelles in water. In addition, PLLA10000-PEG1000-BIO can bind tightly to avidin or streptavidin for protein labeling. PLLA10000-PEG1000-BIO can be used in drug delivery research .
|
-
- HY-167375
-
|
|
Drug Delivery
|
|
PLLA4000-PEG1000-BIO is a polylactic acid derivative that can form micelles in water. In addition, PLLA4000-PEG1000-BIO can bind tightly to avidin or streptavidin for protein labeling. PLLA4000-PEG1000-BIO can be used in drug delivery research .
|
-
- HY-167395
-
|
|
Drug Delivery
|
|
PLLA4000-PEG1000-ALK is a polylactic acid derivative that can form micelles in water. PLLA4000-PEG1000-ALK can be used in drug delivery research .
|
-
- HY-167391
-
|
|
Drug Delivery
|
|
PLLA5000-PEG1000-ALK is a polylactic acid derivative that can form micelles in water. PLLA5000-PEG1000-ALK can be used in drug delivery research .
|
-
- HY-167403
-
|
|
Drug Delivery
|
|
PLLA2000-PEG1000-ALK is a polylactic acid derivative that can form micelles in water. PLLA2000-PEG1000-ALK can be used in drug delivery research .
|
-
- HY-167407
-
|
|
Drug Delivery
|
|
PLLA1000-PEG1000-ALK is a polylactic acid derivative that can form micelles in water. PLLA1000-PEG1000-ALK can be used in drug delivery research .
|
-
- HY-167399
-
|
|
Drug Delivery
|
|
PLLA3000-PEG1000-ALK is a polylactic acid derivative that can form micelles in water. PLLA3000-PEG1000-ALK can be used in drug delivery research .
|
-
- HY-167488
-
|
|
Drug Delivery
|
|
PLLA1000-PEG1000-RhB is a terminal rhodamine-labeled polylactic acid derivative. PLLA1000-PEG1000-RhB can be used to label nanomicelles for real-time monitoring of drug release in vivo .
|
-
- HY-167492
-
|
|
Drug Delivery
|
|
PLLA10000-PEG1000-RhB is a terminal rhodamine-labeled polylactic acid derivative. PLLA10000-PEG1000-RhB can be used to label nanomicelles for real-time monitoring of drug release in vivo .
|
-
- HY-167480
-
|
|
Drug Delivery
|
|
PLLA3000-PEG1000-RhB is a terminal rhodamine-labeled polylactic acid derivative. PLLA3000-PEG1000-RhB can be used to label nanomicelles for real-time monitoring of drug release in vivo .
|
-
- HY-167472
-
|
|
Drug Delivery
|
|
PLLA5000-PEG1000-RhB is a terminal rhodamine-labeled polylactic acid derivative. PLLA5000-PEG1000-RhB can be used to label nanomicelles for real-time monitoring of drug release in vivo .
|
-
- HY-167484
-
|
|
Drug Delivery
|
|
PLLA2000-PEG1000-RhB is a terminal rhodamine-labeled polylactic acid derivative. PLLA2000-PEG1000-RhB can be used to label nanomicelles for real-time monitoring of drug release in vivo .
|
-
- HY-167476
-
|
|
Drug Delivery
|
|
PLLA4000-PEG1000-RhB is a terminal rhodamine-labeled polylactic acid derivative. PLLA4000-PEG1000-RhB can be used to label nanomicelles for real-time monitoring of drug release in vivo .
|
-
- HY-167321
-
|
|
Drug Delivery
|
|
PLLA5000-PEG1000-SPDP is a polylactic acid derivative that can form micelles in water and the SPDP moiety can react with thiols. PLLA5000-PEG1000-SPDP can be used in drug delivery research .
|
-
- HY-167325
-
|
|
Drug Delivery
|
|
PLLA4000-PEG1000-SPDP is a polylactic acid derivative that can form micelles in water and the SPDP moiety can react with thiols. PLLA4000-PEG1000-SPDP can be used in drug delivery research .
|
-
- HY-167305
-
|
|
Drug Delivery
|
|
PLLA3000-PEG1000-Thiol is a polylactic acid derivative that forms micelles in water and initiates biodegradation by attacking ester bonds through hydrolysis. PLLA3000-PEG1000-Thiol can be used in drug delivery research .
|
-
- HY-167333
-
|
|
Drug Delivery
|
|
PLLA2000-PEG1000-SPDP is a polylactic acid derivative that can form micelles in water and the SPDP moiety can react with thiols. PLLA2000-PEG1000-SPDP can be used in drug delivery research .
|
-
- HY-167341
-
|
|
Drug Delivery
|
|
PLLA10000-PEG1000-SPDP is a polylactic acid derivative that can form micelles in water and the SPDP moiety can react with thiols. PLLA10000-PEG1000-SPDP can be used in drug delivery research .
|
-
- HY-167301
-
|
|
Drug Delivery
|
|
PLLA4000-PEG1000-Thiol is a polylactic acid derivative that forms micelles in water and initiates biodegradation by attacking ester bonds through hydrolysis. PLLA4000-PEG1000-Thiol can be used in drug delivery research .
|
-
- HY-167309
-
|
|
Drug Delivery
|
|
PLLA2000-PEG1000-Thiol is a polylactic acid derivative that forms micelles in water and initiates biodegradation by attacking ester bonds through hydrolysis. PLLA2000-PEG1000-Thiol can be used in drug delivery research .
|
-
- HY-167297
-
|
|
Drug Delivery
|
|
PLLA5000-PEG1000-Thiol is a polylactic acid derivative that forms micelles in water and initiates biodegradation by attacking ester bonds through hydrolysis. PLLA5000-PEG1000-Thiol can be used in drug delivery research .
|
-
- HY-167317
-
|
|
Drug Delivery
|
|
PLLA10000-PEG1000-Thiol is a polylactic acid derivative that forms micelles in water and initiates biodegradation by attacking ester bonds through hydrolysis. PLLA10000-PEG1000-Thiol can be used in drug delivery research .
|
-
- HY-167313
-
|
|
Drug Delivery
|
|
PLLA1000-PEG1000-Thiol is a polylactic acid derivative that forms micelles in water and initiates biodegradation by attacking ester bonds through hydrolysis. PLLA1000-PEG1000-Thiol can be used in drug delivery research .
|
-
- HY-167337
-
|
|
Drug Delivery
|
|
PLLA1000-PEG1000-SPDP is a polylactic acid derivative that can form micelles in water and the SPDP moiety can react with thiols. PLLA1000-PEG1000-SPDP can be used in drug delivery research .
|
-
- HY-167329
-
|
|
Drug Delivery
|
|
PLLA3000-PEG1000-SPDP is a polylactic acid derivative that can form micelles in water and the SPDP moiety can react with thiols. PLLA3000-PEG1000-SPDP can be used in drug delivery research .
|
-
- HY-167462
-
|
|
Drug Delivery
|
|
PLLA1000-PEG1000-N3 is a polylactic acid derivative used for encapsulating hydrophobic drugs. PLLA1000-PEG1000-N3 can be used in drug delivery research .
|
-
- HY-167450
-
|
|
Drug Delivery
|
|
PLLA4000-PEG1000-N3 is a polylactic acid derivative used for encapsulating hydrophobic drugs. PLLA4000-PEG1000-N3 can be used in drug delivery research .
|
-
- HY-167458
-
|
|
Drug Delivery
|
|
PLLA2000-PEG1000-N3 is a polylactic acid derivative used for encapsulating hydrophobic drugs. PLLA2000-PEG1000-N3 can be used in drug delivery research .
|
-
- HY-167454
-
|
|
Drug Delivery
|
|
PLLA3000-PEG1000-N3 is a polylactic acid derivative used for encapsulating hydrophobic drugs. PLLA3000-PEG1000-N3 can be used in drug delivery research .
|
-
- HY-167466
-
|
|
Drug Delivery
|
|
PLLA10000-PEG1000-N3 is a polylactic acid derivative used for encapsulating hydrophobic drugs. PLLA10000-PEG1000-N3 can be used in drug delivery research .
|
-
- HY-167446
-
|
|
Drug Delivery
|
|
PLLA5000-PEG1000-N3 is a polylactic acid derivative used for encapsulating hydrophobic drugs. PLLA5000-PEG1000-N3 can be used in drug delivery research .
|
-
- HY-172680
-
|
|
Drug Delivery
|
|
DSPE-PEG1000-VIP is a PEG compound which composed of DSPE and a vasoactive intestinal peptide (VIP). DSPE-PEG1000-VIP can be used for drug delivery .
|
-
- HY-172278
-
|
|
Drug Delivery
|
|
DSPE-PEG1000-CGKRK is a PEG compound which composed of DSPE and a cell-penetrating peptide (CGKRK). DSPE-PEG1000-CGKRK can be used for drug delivery .
|
- HY-167428
-
|
|
Drug Delivery
|
|
PLLA3000-PEG1000-NH2 is a block copolymer based on polylactic acid derivatives that can self-assemble in water. PLLA3000-PEG1000-NH2 can be used in drug delivery research .
|
- HY-167424
-
|
|
Drug Delivery
|
|
PLLA4000-PEG1000-NH2 is a block copolymer based on polylactic acid derivatives that can self-assemble in water. PLLA4000-PEG1000-NH2 can be used in drug delivery research .
|
- HY-167433
-
|
|
Drug Delivery
|
|
PLLA2000-PEG1000-NH2 is a block copolymer based on polylactic acid derivatives that can self-assemble in water. PLLA2000-PEG1000-NH2 can be used in drug delivery research .
|
- HY-167420
-
|
|
Drug Delivery
|
|
PLLA5000-PEG1000-NH2 is a block copolymer based on polylactic acid derivatives that can self-assemble in water. PLLA5000-PEG1000-NH2 can be used in drug delivery research .
|
- HY-167438
-
|
|
Drug Delivery
|
|
PLLA1000-PEG1000-NH2 is a block copolymer based on polylactic acid derivatives that can self-assemble in water. PLLA1000-PEG1000-NH2 can be used in drug delivery research .
|
- HY-167442
-
|
|
Drug Delivery
|
|
PLLA10000-PEG1000-NH2 is a block copolymer based on polylactic acid derivatives that can self-assemble in water. PLLA10000-PEG1000-NH2 can be used in drug delivery research .
|
- HY-145396A
-
- HY-167357
-
|
|
Drug Delivery
|
|
PLLA3000-PEG1000-PLLA3000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA3000-PEG1000-PLLA3000 can be used in drug delivery research .
|
- HY-167363
-
|
|
Drug Delivery
|
|
PLLA2000-PEG1000-PLLA2000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA2000-PEG1000-PLLA2000 can be used in drug delivery research .
|
- HY-167139
-
|
|
Drug Delivery
|
|
PLLA8000-PEG1000-PLLA8000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA8000-PEG1000-PLLA8000 can be used in drug delivery research .
|
- HY-167345
-
|
|
Drug Delivery
|
|
PLLA5000-PEG1000-PLLA5000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA5000-PEG1000-PLLA5000 can be used in drug delivery research .
|
- HY-167120
-
|
|
Drug Delivery
|
|
PLLA6000-PEG1000-PLLA6000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA6000-PEG1000-PLLA6000 can be used in drug delivery research .
|
- HY-167369
-
|
|
Drug Delivery
|
|
PLLA1000-PEG1000-PLLA1000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA1000-PEG1000-PLLA1000 can be used in drug delivery research .
|
- HY-167351
-
|
|
Drug Delivery
|
|
PLLA4000-PEG1000-PLLA4000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA4000-PEG1000-PLLA4000 can be used in drug delivery research .
|
- HY-172279
-
|
|
Drug Delivery
|
|
DSPE-PEG1000-TAT is a PEG compound which composed of DSPE and a cell-penetrating peptide (TAT) (HY-P0281). DSPE-PEG1000-TAT can be used for drug delivery .
|
- HY-173385
-
|
|
Drug Delivery
|
|
Cholesteryl-PEG1000-Azide is a lipid that can be used for drug delivery. Cholesteryl-PEG1000-Azide is attached to the cholesterol backbone with a PEG unit on one side and an azide unit on the other side of the PEG. Cholesteryl-PEG1000-Azide contains an azide group that can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing an alkyne group .
|
- HY-144012D
-
|
16:0 PEG1000 PE; 1,2-Dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-1000] ammonium
|
Drug Delivery
|
|
DPPE-PEG1000 is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.
|
- HY-172274
-
|
|
Drug Delivery
|
|
DSPE-PEG1000-APRPG is a PEG compound which composed of DSPE and a APRPG peptide. DSPE-PEG1000-APRPG can be used for drug delivery .
|
- HY-172481
-
|
|
Drug Delivery
|
|
DSPE-PEG1000-TAASGVRSMH is a PEG compound which composed of DSPE and TAASGVRSMH. TAASGVRSMH has a strong affinity for the NG2 proteoglycan on the PC membrane. DSPE-PEG1000-TAASGVRSMH can be used for drug delivery .
|
- HY-172686
-
|
|
Drug Delivery
|
|
DSPE-PEG1000-CSTSMLKAC is a PEG compound which composed of DSPE and a peptide (CSTSMLKAC). CSTSMLKAC is capable of mediating selective homing of phage to ischemic heart tissue. DSPE-PEG1000-CSTSMLKAC can be used for drug delivery .
|
- HY-172472
-
|
|
Drug Delivery
|
|
DSPE-PEG1000-NGR is a PEG compound which composed of DSPE and an Asn-Gly-Arg (NGR) peptide. NGR peptide can target tumor vascular antigen CD13. DSPE-PEG1000-NGR can be used for drug delivery .
|
- HY-172683
-
|
|
Drug Delivery
|
|
DSPE-PEG1000-GRGDS is a PEG compound which composed of DSPE and an anti-adhesion peptide (GRGDS). GRGDS can block the binding and adhesion of extracellular matrix to cell surface integrins. DSPE-PEG1000-GRGDS can be used for drug delivery .
|
- HY-172725
-
|
|
Drug Delivery
|
|
DSPE-PEG1000-EB1 is a PEG compound which composed of DSPE and pH responsive membrane-penetrating peptide (EB1). DSPE-PEG1000-EB1 can be used for drug delivery .
|
- HY-172277
-
|
|
Drug Delivery
|
|
DSPE-PEG1000-R9 is a PEG compound which composed of DSPE and a poly-arginine-9 peptide (R9). DSPE-PEG1000-R9 can be used for drug delivery .
|
- HY-172695
-
|
|
Drug Delivery
|
|
DSPE-PEG1000-WYRGRL is a PEG compound which composed of DSPE and a cartilage-targeting peptide (WYRGRL). WYRGRL is a collagen II-targeting peptide that can bind to collagen II α1. DSPE-PEG1000-WYRGRL can be used for drug delivery .
|
- HY-172276
-
|
|
Drug Delivery
|
|
DSPE-PEG1000-R8 is a PEG compound which composed of DSPE and a cell-penetrating peptide (R8). pDSPE-PEG1000-R8 can be used for drug delivery .
|
- HY-172484
-
|
|
Drug Delivery
|
|
DSPE-PEG1000-LTLRWVGLMS is a PEG compound which composed of DSPE and a decapeptide (LTLRWVGLMS). The chondroitin sulfate proteoglygan NG2 is a receptor for LTLRWVGLMS. LLRWVGLMS shows the homing of pericytes associated with tumor blood vessels. DSPE-PEG1000-LTLRWVGLMS can be used for drug delivery .
|
- HY-172707
-
|
|
Drug Delivery
|
|
DSPE-PEG1000-PP1 is a PEG compound which composed of DSPE and a PP1 peptide. PP1 peptide targets the inflammatory atherosclerotic plaque. DSPE-PEG1000-PP1 can be used for drug delivery .
|
- HY-168374A
-
|
|
Drug Delivery
|
|
DSPE-PEG1000-mannose is an amphiphilic molecule that can be used to synthesize lipid nanoparticles .
|
- HY-172270
-
|
|
Drug Delivery
|
|
DSPE-PEG1000-PTP is synthesised by conjugating the amino group of plectin-1 peptide (PTP) with DSPE-PEG-NHS ester via amide bonds. DSPE-PEG1000-PTP can be used to construct drug delivery vectors .
|
- HY-172280
-
|
|
Drug Delivery
|
|
DSPE-PEG1000-Octreotide is a PEG compound which composed of DSPE and a Octreotide (HY-P0036). Octreotide is a somatostatin receptor agonist. Octreotide has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly. DSPE-PEG1000-Octreotide can be used for drug delivery .
|
- HY-172698
-
|
|
Drug Delivery
|
|
DSPE-PEG1000-ANG is a PEG compound which composed of DSPE and a dual-targeting ligand (Angiopep-2, ANG). ANG exhibits high LRP1 binding efficiency and has been used for glioma-targeting delivery. DSPE-PEG1000-ANG can be used for drug delivery .
|
- HY-172701
-
|
|
Drug Delivery
|
|
DSPE-PEG1000-NYZL1 is a PEG compound which composed of DSPE and a NYZL1 peptide. NYZL1 can specifically bind to bladder cancer tissues and cells. DSPE-PEG1000-NYZL1 can be used for drug delivery .
|
- HY-172466
-
|
|
Drug Delivery
|
|
DSPE-PEG1000-CTT2 is a PEG compound which composed of DSPE and a gelatinase inhibitor (CTT2 (CTTHWGFTLC)). CTT2 (CTTHWGFTLC) has the ability to specifically target tumors. DSPE-PEG1000-CTT2 can be used for drug delivery .
|
- HY-172469
-
|
|
Drug Delivery
|
|
DSPE-PEG1000-GE11 is a PEG compound which composed of DSPE and an EGFR targeting peptide (GE11). GE11 can be used for EGFR overexpressed cancer cells. DSPE-PEG1000-GE11 can be used for drug delivery .
|
- HY-172463
-
|
|
Drug Delivery
|
|
DSPE-PEG1000-cRGD is a PEG compound which composed of DSPE and an αvβ3 targeting peptide (cRGD). cRGD peptide can specifically bind to αvβ3 on the surface of many cancer cells and neovascular cells. DSPE-PEG1000-cRGD can be used for drug delivery .
|
- HY-172502
-
|
|
Drug Delivery
|
|
DSPE-PEG1000-KAA is a PEG compound which composed of DSPE and a CKAAKNK peptide (KAA). KAA specifically binds to tumor vessels in RIP-Tag2 transgenic mice. DSPE-PEG1000-KAA can be used for drug delivery .
|
- HY-172722
-
|
|
Drug Delivery
|
|
DSPE-PEG1000-T7 is a PEG compound which composed of DSPE and a transferrin receptor (TfR) peptide (T7). T7 (HAIYPRH) specifically binds to TfR (transferrin receptor). DSPE-PEG1000-T7 can be used for drug delivery .
|
- HY-172475
-
|
|
Drug Delivery
|
|
DSPE-PEG1000-YIGSR is a PEG compound which composed of DSPE and a biomimetic peptide YIGSR. YIGSR interacts with the 67 kDa laminin binding protein (LBP) and promotes adhesion and spreading of a large number of cell types including endothelial cells, fibroblasts and smooth muscle cells. DSPE-PEG1000-YIGSR can be used for drug delivery .
|
- HY-172496
-
|
|
Drug Delivery
|
|
DSPE-PEG1000-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG1000-CREKA can be used for drug delivery .
|
- HY-172281
-
|
|
Drug Delivery
|
|
DSPE-PEG1000-CCK8 is a PEG compound which composed of DSPE and a Cholecystokinin-8 (CCK8). Cholecystokinin-8 has the activity of peptide regulating gallbladder contraction and digestive system function. DSPE-PEG1000-CCK8 can be used for drug delivery .
|
- HY-173381A
-
|
Cholesteryl biotinyl(polyethyleneglycol)-1000 carbamate
|
Drug Delivery
|
|
Cholesteryl-PEG1000-Biotin is a lipid product. Cholesteryl-PEG1000-Biotin is a cholesterol backbone attached to one side of a PEG unit and a Biotin unit on the other side. Biotin is an enzyme cofactor that can be used to label proteins, and PEG is a low-toxic, hydrophilic, water-soluble polymer. Cholesteryl-PEG1000-Biotin can be used for drug circulation time studies .
|
- HY-172493
-
|
|
Drug Delivery
|
|
DSPE-PEG1000-iRGD is a PEG compound which composed of DSPE and an αv-integrins targeting peptide (iRGD). iRGD peptide binds to αv-integrins, and then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties. DSPE-PEG1000-iRGD can be used for drug delivery .
|
- HY-172478
-
|
|
Drug Delivery
|
|
DSPE-PEG1000-F3 is a PEG compound which composed of DSPE and a nucleolin targeting peptide (F3). F3 peptide can specifically bind to cell surface nucleolin and undergo an effective cell surface to nucleus transport. DSPE-PEG1000-F3 can be used for drug delivery .
|
- HY-172487
-
|
|
Drug Delivery
|
|
DSPE-PEG1000-K237 is a PEG compound which composed of DSPE and a KDR targeting peptide (K237). K237 can functionally disrupt the interaction between VEGF and the KDR receptor and cause potent biological effects that include the inhibition of angiogenesis and tumor growth. DSPE-PEG1000-K237 can be used for drug delivery .
|
- HY-172689
-
|
|
Drug Delivery
|
|
DSPE-PEG1000-THRPPMWSPVWP is a PEG compound which composed of DSPE and a transferrin receptor (TfR) peptide (THRPPMWSPVWP). THRPPMWSPVWP binds to the TfR and is subsequently internalized into TfR-expressing cells .
|
- HY-172275
-
|
|
Drug Delivery
|
|
DSPE-PEG1000-pPB is a PEG compound which composed of DSPE and a cyclic oligopeptide (pPB). pPB has a strong binding affinity with PDGFRβ, which is overexpressed on activated hepatic stellate cells (HSC). DSPE-PEG1000-pPB can be used for drug delivery .
|
- HY-172273
-
|
|
Drug Delivery
|
|
DSPE-PEG1000-M2pep is a PEG compound which composed of DSPE and a M2-polarized macrophages targeting peptide (M2pep). M2pep is conjugated to a proapoptotic peptide as monovalent or multivalent ligands to concentrate the toxic effect of the peptide to M2 macrophages. DSPE-PEG1000-M2pep can be used for drug delivery .
|
- HY-172710
-
|
|
Drug Delivery
|
|
DSPE-PEG1000-R6H4 is a PEG compound which composed of DSPE and pH responsive membrane-penetrating peptide (R6H4). R6H4 can be used for pH responsive anticancer drug delivery purposes. DSPE-PEG1000-R6H4 can be used for drug delivery .
|
- HY-172490
-
|
|
Drug Delivery
|
|
DSPE-PEG1000-ESBP is a PEG compound which composed of DSPE and a E-selectin-binding peptide (ESBP). As a tumor-targeting peptide, ESBP can specifically recognize and bind to receptors or markers on the surface of tumor cells .
|
- HY-172499
-
|
|
Drug Delivery
|
|
DSPE-PEG1000-SP94 is a PEG compound which composed of DSPE and a cell-penetrating peptide (SP94). SP94 shows specific binding to hepatocellular carcinoma (HCC) cells .
|
- HY-172704
-
|
|
Drug Delivery
|
|
DSPE-PEG1000-RVG29 is a PEG compound which composed of DSPE and a Rabies virus glycoprotein 29 (RVG29). RVG29 can bind specifically to the nicotinic acetylcholine receptor (nAChR) at the blood-brain barrier (BBB) and cross over the BBB .
|
- HY-172283
-
|
|
Drug Delivery
|
|
DSPE-PEG1000-BR2 is a PEG compound which composed of DSPE and a BR2. BR2 is a targeting peptide composed of 17 amino acids with the sequence RAGLQFPVGRLLRRLLR. It has the ability to assist cells to penetrate the membrane and can specifically target certain cells or tissues .
|
- HY-172272
-
|
|
Drug Delivery
|
|
DSPE-PEG1000-A7R is a PEG compound which composed of DSPE and a tumor vascular targeting peptide (A7R). A7R exhibits high affinity and specificity for VEGFR-2, which is overexpressed in various tumors .
|
- HY-172713
-
|
|
Drug Delivery
|
|
DSPE-PEG1000-MPG is a PEG compound which composed of DSPE and a peptide vector (MPG). MPG is derived from both the nuclear localisation sequence (NLS) of SV40 large T antigen and the fusion peptide domain of HIV-1 gp41. MPG could deliver short oligonucleotides into cells efficiently and independently of the endosomal pathway .
|
- HY-172271
-
|
|
Drug Delivery
|
|
DSPE-PEG1000-LyP-1 is a PEG compound which composed of DSPE and a nine residue peptide (LyP-1) (HY-P2526). LyP-1 targets tumor-associated lymphatic vessels and macrophages .
|
- HY-172270D
-
|
|
Drug Delivery
|
|
DSPE-PEG1000-PTP is synthesised by conjugating the amino group of plectin-1 peptide (PTP) with DSPE-PEG-NHS ester via amide bonds. DSPE-PEG1000-PTP can be used to construct drug delivery vectors .
|
- HY-172270C
-
|
|
Drug Delivery
|
|
DSPE-PEG1000-PTP is synthesised by conjugating the amino group of plectin-1 peptide (PTP) with DSPE-PEG-NHS ester via amide bonds. DSPE-PEG1000-PTP can be used to construct drug delivery vectors .
|
- HY-172270A
-
|
|
Drug Delivery
|
|
DSPE-PEG1000-PTP is synthesised by conjugating the amino group of plectin-1 peptide (PTP) with DSPE-PEG-NHS ester via amide bonds. DSPE-PEG1000-PTP can be used to construct drug delivery vectors .
|
| Cat. No. |
Product Name |
|
Classification |
-
- HY-167395
-
|
|
|
Alkynes
|
|
PLLA4000-PEG1000-ALK is a polylactic acid derivative that can form micelles in water. PLLA4000-PEG1000-ALK can be used in drug delivery research .
|
-
- HY-167391
-
|
|
|
Alkynes
|
|
PLLA5000-PEG1000-ALK is a polylactic acid derivative that can form micelles in water. PLLA5000-PEG1000-ALK can be used in drug delivery research .
|
-
- HY-167403
-
|
|
|
Alkynes
|
|
PLLA2000-PEG1000-ALK is a polylactic acid derivative that can form micelles in water. PLLA2000-PEG1000-ALK can be used in drug delivery research .
|
-
- HY-167407
-
|
|
|
Alkynes
|
|
PLLA1000-PEG1000-ALK is a polylactic acid derivative that can form micelles in water. PLLA1000-PEG1000-ALK can be used in drug delivery research .
|
-
- HY-167399
-
|
|
|
Alkynes
|
|
PLLA3000-PEG1000-ALK is a polylactic acid derivative that can form micelles in water. PLLA3000-PEG1000-ALK can be used in drug delivery research .
|
-
- HY-167462
-
|
|
|
Azide
|
|
PLLA1000-PEG1000-N3 is a polylactic acid derivative used for encapsulating hydrophobic drugs. PLLA1000-PEG1000-N3 can be used in drug delivery research .
|
-
- HY-167450
-
|
|
|
Azide
|
|
PLLA4000-PEG1000-N3 is a polylactic acid derivative used for encapsulating hydrophobic drugs. PLLA4000-PEG1000-N3 can be used in drug delivery research .
|
-
- HY-167458
-
|
|
|
Azide
|
|
PLLA2000-PEG1000-N3 is a polylactic acid derivative used for encapsulating hydrophobic drugs. PLLA2000-PEG1000-N3 can be used in drug delivery research .
|
-
- HY-167454
-
|
|
|
Azide
|
|
PLLA3000-PEG1000-N3 is a polylactic acid derivative used for encapsulating hydrophobic drugs. PLLA3000-PEG1000-N3 can be used in drug delivery research .
|
-
- HY-167466
-
|
|
|
Azide
|
|
PLLA10000-PEG1000-N3 is a polylactic acid derivative used for encapsulating hydrophobic drugs. PLLA10000-PEG1000-N3 can be used in drug delivery research .
|
-
- HY-167446
-
|
|
|
Azide
|
|
PLLA5000-PEG1000-N3 is a polylactic acid derivative used for encapsulating hydrophobic drugs. PLLA5000-PEG1000-N3 can be used in drug delivery research .
|
-
- HY-173385
-
|
|
|
Azide
|
|
Cholesteryl-PEG1000-Azide is a lipid that can be used for drug delivery. Cholesteryl-PEG1000-Azide is attached to the cholesterol backbone with a PEG unit on one side and an azide unit on the other side of the PEG. Cholesteryl-PEG1000-Azide contains an azide group that can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing an alkyne group .
|
| Cat. No. |
Product Name |
|
Classification |
-
- HY-Y0873G
-
|
Polyethylene glycol 1000
|
|
Bases
|
|
PEG1000 can be used as an excipient, such as Ointment base, lubricant, etc. Pharmaceutical excipients, or pharmaceutical auxiliaries, refer to other chemical substances used in the pharmaceutical process other than pharmaceutical ingredients. Pharmaceutical excipients generally refer to inactive ingredients in pharmaceutical preparations, which can improve the stability, solubility and processability of pharmaceutical preparations. Pharmaceutical excipients also affect the absorption, distribution, metabolism, and elimination (ADME) processes of co-administered drugs .
|
-
- HY-155927
-
|
14:0 PEG1000 PE ammonium; 1,2-Dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-1000] ammonium
|
|
Pegylated Lipids
|
|
DMPE-PEG1000 ammonium (14:0 PEG1000 PE ammonium) is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.
|
-
- HY-155932
-
|
DOPE-PEG1000 ammonium; 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-1000] ammonium
|
|
Pegylated Lipids
|
|
18:1 PEG1000 PE ammonium (DOPE-PEG1000 ammonium) is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.
|
-
- HY-144012D
-
|
16:0 PEG1000 PE; 1,2-Dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-1000] ammonium
|
|
Pegylated Lipids
|
|
DPPE-PEG1000 is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.
|
-
- HY-172274
-
|
|
|
Pegylated Lipids
|
|
DSPE-PEG1000-APRPG is a PEG compound which composed of DSPE and a APRPG peptide. DSPE-PEG1000-APRPG can be used for drug delivery .
|
-
- HY-172276
-
|
|
|
Pegylated Lipids
|
|
DSPE-PEG1000-R8 is a PEG compound which composed of DSPE and a cell-penetrating peptide (R8). pDSPE-PEG1000-R8 can be used for drug delivery .
|
-
- HY-172270
-
|
|
|
Pegylated Lipids
|
|
DSPE-PEG1000-PTP is synthesised by conjugating the amino group of plectin-1 peptide (PTP) with DSPE-PEG-NHS ester via amide bonds. DSPE-PEG1000-PTP can be used to construct drug delivery vectors .
|
-
- HY-172463
-
|
|
|
Pegylated Lipids
|
|
DSPE-PEG1000-cRGD is a PEG compound which composed of DSPE and an αvβ3 targeting peptide (cRGD). cRGD peptide can specifically bind to αvβ3 on the surface of many cancer cells and neovascular cells. DSPE-PEG1000-cRGD can be used for drug delivery .
|
-
- HY-172502
-
|
|
|
Pegylated Lipids
|
|
DSPE-PEG1000-KAA is a PEG compound which composed of DSPE and a CKAAKNK peptide (KAA). KAA specifically binds to tumor vessels in RIP-Tag2 transgenic mice. DSPE-PEG1000-KAA can be used for drug delivery .
|
-
- HY-172722
-
|
|
|
Pegylated Lipids
|
|
DSPE-PEG1000-T7 is a PEG compound which composed of DSPE and a transferrin receptor (TfR) peptide (T7). T7 (HAIYPRH) specifically binds to TfR (transferrin receptor). DSPE-PEG1000-T7 can be used for drug delivery .
|
-
- HY-172496
-
|
|
|
Pegylated Lipids
|
|
DSPE-PEG1000-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG1000-CREKA can be used for drug delivery .
|
-
- HY-172493
-
|
|
|
Pegylated Lipids
|
|
DSPE-PEG1000-iRGD is a PEG compound which composed of DSPE and an αv-integrins targeting peptide (iRGD). iRGD peptide binds to αv-integrins, and then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties. DSPE-PEG1000-iRGD can be used for drug delivery .
|
-
- HY-172275
-
|
|
|
Pegylated Lipids
|
|
DSPE-PEG1000-pPB is a PEG compound which composed of DSPE and a cyclic oligopeptide (pPB). pPB has a strong binding affinity with PDGFRβ, which is overexpressed on activated hepatic stellate cells (HSC). DSPE-PEG1000-pPB can be used for drug delivery .
|
-
- HY-172273
-
|
|
|
Pegylated Lipids
|
|
DSPE-PEG1000-M2pep is a PEG compound which composed of DSPE and a M2-polarized macrophages targeting peptide (M2pep). M2pep is conjugated to a proapoptotic peptide as monovalent or multivalent ligands to concentrate the toxic effect of the peptide to M2 macrophages. DSPE-PEG1000-M2pep can be used for drug delivery .
|
-
- HY-172499
-
|
|
|
Pegylated Lipids
|
|
DSPE-PEG1000-SP94 is a PEG compound which composed of DSPE and a cell-penetrating peptide (SP94). SP94 shows specific binding to hepatocellular carcinoma (HCC) cells .
|
-
- HY-172704
-
|
|
|
Pegylated Lipids
|
|
DSPE-PEG1000-RVG29 is a PEG compound which composed of DSPE and a Rabies virus glycoprotein 29 (RVG29). RVG29 can bind specifically to the nicotinic acetylcholine receptor (nAChR) at the blood-brain barrier (BBB) and cross over the BBB .
|
-
- HY-172283
-
|
|
|
Pegylated Lipids
|
|
DSPE-PEG1000-BR2 is a PEG compound which composed of DSPE and a BR2. BR2 is a targeting peptide composed of 17 amino acids with the sequence RAGLQFPVGRLLRRLLR. It has the ability to assist cells to penetrate the membrane and can specifically target certain cells or tissues .
|
-
- HY-172272
-
|
|
|
Pegylated Lipids
|
|
DSPE-PEG1000-A7R is a PEG compound which composed of DSPE and a tumor vascular targeting peptide (A7R). A7R exhibits high affinity and specificity for VEGFR-2, which is overexpressed in various tumors .
|
-
- HY-172271
-
|
|
|
Pegylated Lipids
|
|
DSPE-PEG1000-LyP-1 is a PEG compound which composed of DSPE and a nine residue peptide (LyP-1) (HY-P2526). LyP-1 targets tumor-associated lymphatic vessels and macrophages .
|
-
- HY-172270A
-
|
|
|
Pegylated Lipids
|
|
DSPE-PEG1000-PTP is synthesised by conjugating the amino group of plectin-1 peptide (PTP) with DSPE-PEG-NHS ester via amide bonds. DSPE-PEG1000-PTP can be used to construct drug delivery vectors .
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
